Search Results - "VanderWeele, David James"

A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer by VanderWeele, David James, Fenton, Sarah Elizabeth, Auffenberg, Gregory, Jovanovic, Borko, Hussain, Maha H. A.

“…Abstract only TPS286 Background: Most patients (pts) who die of prostate cancer (pca) had potentially curable localized disease when first diagnosed, but their…”
Get full text

A phase I trial of androgen deprivation, darolutamide, and ipatasertib in a safety cohort with castration-resistant prostate cancer (ADDITION) by Fenton, Sarah Elizabeth, Springsdorf, Rachel, Kenny, Siobhan, Bere, Lauren, Ross, Ashley, Kocherginsky, Masha, Hussain, Maha H. A., VanderWeele, David James

“…174 Background: Alterations activating the PI3K-AKT pathway are found in 40-50% of patients with aggressive prostate cancer. This leads to an abrogated…”
Get full text

Practice patterns in prostate cancer therapy among healthcare professionals: Comparison with expert recommendations from an online tool by Becker, Marie N., Rosenthal, Kristen M., Dorff, Tanya B., McKay, Rana R., Schweizer, Michael Thomas, VanderWeele, David James, Morgans, Alicia K.

“…e13549 Background: The treatment landscape of prostate cancer (PC) is complex, and recent approvals of new agents and regimens further challenge healthcare…”
Get full text

Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression by Stewart, Tyler F., Fenton, Sarah Elizabeth, Nazari, Shayan, Elliott, Andrew, Garje, Rohan, Salmasi, Amirali, Bagrodia, Aditya, Nabhan, Chadi, VanderWeele, David James, McKay, Rana R.

“…4585 Background: Advanced UC is a devastating disease, however recent advances with antibody drug conjugates (ADCs), including enfortumab vedotin (EV), have…”
Get full text

A phase II trial with copanlisib plus avelumab as maintenance therapy for metastatic bladder cancer after platinum-based chemotherapy by Farrukh, Hizra, Zhu, Zheng, Zhu, Shaoming, Montgomery, Robert Bruce, Meeks, Joshua J, VanderWeele, David James, Wong, Yu-Ning, Lew, Robert A, Pan, Chong-xian

“…TPS4610 Background: Bladder cancer is the tenth most common malignancy and the fourteenth most common cause of cancer death worldwide. Currently,…”
Get full text

A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183) by Hussain, Maha H. A., Kocherginsky, Masha, Singh, Parminder, Myint, Zin, Jiang, Di Maria, Wulff-Burchfield, Elizabeth Marie, Sharon, Elad, Piekarz, Richard, Meeks, Joshua J, VanderWeele, David James

“…506 Background: Despite response to systemic therapy, few metastatic urothelial carcinoma (mUC) patients (pts) achieve durable responses. Mutations in the…”
Get full text

A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183) by Hussain, Maha H. A., Kocherginsky, Masha, Singh, Parminder, Tan, Winston, Myint, Zin, Jiang, Di (Maria), Wulff-Burchfield, Elizabeth Marie, Ma, Yangruijue, Sharon, Elad, Piekarz, Richard, Meeks, Joshua J, VanderWeele, David James

“…4574 Background: Mutations of COMPASS-related proteins KMT2D, KMT2C, and KDM6A are observed in 66% of advanced urothelial carcinomas (UC). In vivo, the…”
Get full text

Clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer by Fenton, Sarah Elizabeth, Kocherginsky, Masha, VanderWeele, David James, Morgans, Alicia K., Palmbos, Phillip Lee, Meeks, Joshua J., Benning, James, Martone, Brenda K., Szymaniak, Brittany, Hussain, Maha H. A.

“…e17049 Background: Although prostate cancer (PC) is heterogeneous, the rate of patients diagnosed with aggressive metastatic disease at a young age has been…”
Get full text

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer by VanderWeele, David James, Kocherginsky, Masha, Munir, Sabah, Martone, Brenda K., Morgans, Alicia K., Stadler, Walter Michael, Abdulkadir, Sarki, Hussain, Maha H. A.

“…Abstract only 84 Background: Ephrin receptors and their membrane-localized ligands induce bidirectional signaling and facilitate tumor-stroma interactions…”
Get full text

Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC) by Ryan, Charles J., Cao, Qing, De Souza, Andre Luiz, VanderWeele, David James, Bryce, Alan Haruo, Kelly, William Kevin, Jha, Gautam Gopalji, Barata, Pedro C., Sartor, A. Oliver, Stadler, Walter Michael, Dhawan, Mallika Sachdev, Morgans, Alicia K., Antonarakis, Emmanuel S.

“…5071 Background: Best treatment of mCSPC involves doublet therapy (ADT + novel hormonal agent) or triplet therapy (ADT + novel hormone + docetaxel); however,…”
Get full text

Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC) by Rao, Arpit, Heller, Glenn, Ryan, Charles J., VanderWeele, David James, Lewis, Lionel D, Tan, Alan, Watt, Colleen, Chen, Ronald C., Kohli, Manish, Barata, Pedro C., Gartrell, Benjamin Adam, Grubb, Robert, Dueck, Amylou C., Wen, Yujia, Morris, Michael J.

“…TPS277 Background: Despite a growing number of treatment options for first-line mCRPC, approximately 40% of patients (pts) have radiographic progression within…”
Get full text

A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer by Fenton, Sarah Elizabeth, Kocherginsky, Masha, VanderWeele, David James, Morgans, Alicia K., Palmbos, Phillip Lee, Meeks, Joshua J, Benning, James, Kenny, Siobhan, Martone, Brenda K., Szymaniak, Brittany, Hussain, Maha H. A.

“…266 Background: The frequency of young men with aggressive prostate cancer (PC) at diagnosis is increasing. Clinical, environmental, and genetic drivers of…”
Get full text

Treatment decision making in metastatic prostate cancer (mPC) by Morgans, Alicia K., Fought, Angela, Lee, Benjamin, VanderWeele, David James, Hussain, Maha H. A., Moses, Kelvin A., Penson, David F.

“…Abstract only 224 Background: Multiple treatments exist for mPC, and optimal treatment choice is not defined. Shared decision making (SDM) in which physicians…”
Get full text

A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183) by Meeks, Joshua J., Shilatifard, Ali, Miller, Stephen D., Morgans, Alicia K., VanderWeele, David James, Kocherginsky, Masha, Hussain, Maha H. A.

“…Abstract only TPS607 Background: Few patients with metastatic urothelial carcinoma (UC) achieve a durable response despite early stabilization with…”
Get full text

CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC) by Rao, Arpit, Ryan, Charles J., VanderWeele, David James, Heller, Glenn, Lewis, Lionel D, Watt, Colleen, Chen, Ronald C., Grubb, Robert, Hahn, Olwen Mary, Beltran, Himisha, Morris, Michael J.

“…Abstract only TPS181 Background: Treatment with novel antiandrogens (NAA) and androgen deprivation therapy prolongs life in men with mCRPC but approximately…”
Get full text

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC) by Rao, Arpit, Heller, Glenn, Ryan, Charles J., VanderWeele, David James, Lewis, Lionel D, Tan, Alan, Watt, Colleen, Chen, Ronald C., Kohli, Manish, Barata, Pedro C., Gartrell, Benjamin Adam, Grubb, Robert, Dueck, Amylou C., Wen, Yujia, Morris, Michael J.

“…TPS5107 Background: Despite a growing number of treatment options for first line mCRPC, approximately 40% of patients (pts) have radiographic progression…”
Get full text

Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC) by Aggarwal, Rahul Raj, Vuky, Jacqueline, VanderWeele, David James, Rettig, Matthew, Heath, Elisabeth I., Beer, Tomasz M., Huang, Jiaoti, Pawlowska, Nela, Sinit, Ryan, Abbey, Jill, Liu, Bin, Nasoff, Marc, Dorr, Andrew, Small, Eric Jay

“…3001 Background: FOR46, a fully human antibody (ab) conjugated to monomethyl auristatin E (MMAE), targets a tumor selective epitope of CD46, which is highly…”
Get full text

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC) by Rao, Arpit, Heller, Glenn, Ryan, Charles J., VanderWeele, David James, Lewis, Lionel D, Tan, Alan, Watt, Colleen, Chen, Ronald C., Kohli, Manish, Barata, Pedro C., Gartrell, Benjamin Adam, Grubb, Robert, Dueck, Amylou C., Wen, Yujia, Morris, Michael J.

“…Abstract only TPS194 Background: Despite a growing number of treatment options for first line mCRPC, approximately 40% of patients (pts) have radiographic…”
Get full text

Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response by Numan, Yazan, Zhao, Jonathan, Tang, Song, Zhang, Youbin, Zhang, Qiang, Jovanovic, Borko, VanderWeele, David James, Morgans, Alicia K., Cristofanilli, Massimo, Yu, Jindan, Hussain, Maha H. A.

“…Abstract only TPS275 Background: Androgen deprivation therapy (ADT) is the backbone of therapy for metastatic hormone sensitive prostate cancer (mHSPC)…”
Get full text

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC) by Burns, Michael C., Sagar, Vinay, Jovanovic, Borko, Morgans, Alicia K., VanderWeele, David James, Quinn, David I., Stadler, Walter Michael, Abdulkadir, Sarki, Hussain, Maha H. A.

“…Abstract only TPS274 Background: The EphB4/EphrinB2 pathway is a promising therapeutic target for patients with mCRPC. EphB4 expression is increased in…”
Get full text